Recent Advances in the Understanding of CSCs and Treatments Targeting Them
DOI:
https://doi.org/10.47611/jsrhs.v13i4.8212Keywords:
CSC, Cancer Stem Cells, Stem Cells, Cancer Treatment, New TherapiesAbstract
This study overviews the biology of the cancer stem cell (CSC) and current progress made in treatments targeting them. CSCs help cancer to resist current mainstream cancer treatments and allow cancer to recur even after it is considered cured. CSCs are cancer cells that are both low in number and divide slowly, or even stay quiescent (not multiplying). This allows them to avoid being targeted by chemotherapy and other therapies that are created to target the rapidly dividing cancer cells. In order to combat the CSCs researchers have looked at biomarkers that are specific to CSCs, however it is difficult. CSCs have many biomarkers in common with other cancer cells or with non-cancerous counterparts. In addition, biomarkers that are present in one type of cancer may not be present elsewhere. Despite this, many CSC biomarkers have been identified as possible means to target them. Other biomarkers, like CD26, have been identified as early signs of an aggressive cancer and can serve as a warning, allowing time for preparation. Many more currently ongoing studies are also looking for even more biomarkers that can be used to target CSCs effectively. Other studies look at possible ways to use those biomarkers against cancer, using methods such as immunotherapy. While no definitive method for combating CSCs currently exists as of now the subject is showing great potential as a method to help treat cancer.
Downloads
References or Bibliography
Barbato, L., Bocchetti, M., Anna Di Biase, & Tarik Regad. (2019). CSCs and Targeting Strategies. Cells, 8(8), 926–926. https://doi.org/10.3390/cells8080926
Batlle, E., & Clevers, H. (2017). CSCs revisited. Nature Medicine, 23(10), 1124–1134. https://doi.org/10.1038/nm.4409
Bianchi, F. (2024). Clinicaltrials.gov. https://clinicaltrials.gov/study/NCT06409416?cond=cancer%20&term=cancer%20stem%20cell&intr=biomarker&checkSpell=&rank=3
Biserova, K., Arvids Jakovlevs, Romans Uljanovs, & Ilze Strumfa. (2021). CSCs: Significance in Origin, Pathogenesis and Treatment of Glioblastoma. Cells, 10(3), 621–621. https://doi.org/10.3390/cells10030621
Erina Vlashi, & Pajonk, F. (2015). CSCs, cancer cell plasticity and radiation therapy. Seminars in Cancer Biology, 31, 28–35. https://doi.org/10.1016/j.semcancer.2014.07.001
Granda, F. (2024). Clinicaltrials.gov. https://clinicaltrials.gov/study/NCT06348693?cond=cancer%20&term=cancer%20stem%20cell&intr=biomarker&checkSpell=&rank=10
Khaled, S. (2024). Clinicaltrials.gov. https://clinicaltrials.gov/study/NCT04312607?cond=cancer%20stem%20cell&term=biomarker&rank=1
Nassar, D., & Cédric Blanpain. (2016). CSCs: Basic Concepts and
Therapeutic Implications. Annual Review of Pathology Mechanisms of Disease,
(1), 47–76. https://doi.org/10.1146/annurev-pathol-012615-044438
Plaks, V., Kong, N., & Werb, Z. (2015). The CSC Niche: How Essential Is the Niche in Regulating Stemness of Tumor Cells? Cell Stem Cell, 16(3), 225–238. https://doi.org/10.1016/j.stem.2015.02.015
Quaglino, E., Conti, L., & Cavallo, F. (2020). Breast CSC antigens as targets for immunotherapy. Seminars in Immunology, 47, 101386–101386. https://doi.org/10.1016/j.smim.2020.101386
Sun, J.-H., Luo, Q., Liu, L.-L., & Song, G.-B. (2016). Liver CSC markers: Progression and therapeutic implications. World Journal of Gastroenterology, 22(13), 3547–3547. https://doi.org/10.3748/wjg.v22.i13.3547
Tran, T.-O., Thanh Hoa Vo, Lam, T., & Le. (2023). ALDH2 as a potential stem cell-related biomarker in lung adenocarcinoma: Comprehensive multi-omics analysis. Computational and Structural Biotechnology Journal, 21, 1921–1929. https://doi.org/10.1016/j.csbj.2023.02.045
University of Minnesota, M. C. C. (2024). Clinicaltrials.gov. https://clinicaltrials.gov/study/NCT01171469?cond=NCT01171469&rank=1
Walcher, L., Kistenmacher, A.-K., Suo, H., Reni Kitte, Dluczek, S., Strauß, A., André-René Blaudszun, Tetyana Yevsa, Fricke, S., & Uta Kossatz-Boehlert. (2020). CSCs—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.01280
World. (2022, February 3). Cancer. Who.int; World Health Organization: WHO. https://www.who.int/news-room/fact-sheets/detail/cancer
Published
How to Cite
Issue
Section
Copyright (c) 2024 Parthapratim Biswas; Prahlad Parajuri, Jothsna Kethar
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
